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The identification of oncogenic driver mutations in non-small cell lung cancer (NSCLC) has
led to a paradigm shift and the development of specific molecular treatments. Tumors
harboring a rearranged EML4–ALK fusion oncogene are highly sensitive to therapy with
ALK-targeted inhibitors. Crizotinib is the first approved treatment for advanced lung tumors
containing this genetic abnormality. In this mini review, we discuss the existing data on
crizotinib as well as ongoing trials involving this medication. A brief overview of the known
resistance mechanisms to crizotinib will also be presented followed by a summary of
the ongoing trials involving next-generation ALK-inhibitors or other targeted therapies in
patients with ALK NSCLC.+
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INTRODUCTION
Treatment for non-small cell lung cancer (NSCLC) has histor-
ically consisted of cytotoxic chemotherapy. Recent advances in
molecular biology had led to the discovery of oncogenic dri-
ver mutations with subsequent development of oral agents that
target these molecular pathways. In NSCLC, the main two dri-
ver mutations, with FDA approved targeted therapies, consist
of echinoderm microtubule protein like-4/anaplastic lymphoma
kinase (EML-4/ALK) translocations and epidermal growth factor
receptor (EGFR) mutations. Crizotinib is the first FDA approved
treatment for patients with ALK+ NSCLC. To this date, only the
final data from one phase III randomized trial has been published,
evaluating the use of crizotinib as a second-line therapy (1). Multi-
ple phase III randomized trials are in progress to assess the efficacy
of crizotinib as first-line chemotherapy. Eventually, most patients
on treatment with crizotinib develop resistance to this drug within
1 year of treatment. Most clinical trials in progress in the ALK+
patient population involve “new-generation ALK-inhibitors,” or
crizotinib in combination with novel drugs to bypass known
resistance mechanisms.
The scope of this review article is twofold. First, the existing
data on crizotinib will be presented as well ongoing trials involving
this medication. Second, a brief overview of the known resistance
mechanisms to crizotinib will be presented followed by a summary
of the ongoing trials involving newer generation ALK-inhibitors
or other targeted therapies in patients with ALK+ NSCLC.
ALK FUSION GENE AND ITS TARGET CRIZOTINIB
Crizotinib is an orally active inhibitor of multiple tyrosine kinase
inhibitors (TKIs), including ALK, c-Met, hepatocyte growth fac-
tor receptor (HGFR), and c-ros oncogene 1 (ROS1) (Figure 1)
(2). In 2007, the ALK gene rearrangement in which the 5′ end of
EML4 gene is fused to the 3′ end of ALK was first identified by
Soda et al. in NSCLC cell lines (3). The fusion protein resulting
from this translocation has constitutive kinase activity, leading
to downstream activation of multiple diverse signaling cascades
involved in cell proliferation and carcinogenesis. Currently, mul-
tiple EML4–ALK fusion combinations have been identified (4).
All these fusion proteins have a similar ALK kinase domain, but
differ in the EML4 breakpoint. Pre-clinical data from in vitro stud-
ies suggested different crizotinib sensitivity for each variant of the
EML4–ALK fusion protein (5). However, a subgroup analysis from
the phase I trial of crizotinib failed to demonstrate such correlation
between variant fusion proteins and clinical response to therapy
(6). In addition, fusions of ALK with other partners including
TRK-fused gene TFG and KIF5B have also been described in
lung cancer patients, but appear to be much less common than
EML4-ALK (7).
CLINICAL TRIALS INVOLVING CRIZOTINIB
In 2013, Shaw et al. published the first phase III randomized
trial involving crizotinib in the second-line setting (1). Patients
with locally advanced or metastatic ALK+NSCLC were randomly
assigned to receive oral treatment with crizotinib (250 mg) twice
daily or intravenous chemotherapy with either pemetrexed or doc-
etaxel. The median progression-free survival was 7.7 months in the
crizotinib group and 3.0 months in the chemotherapy group. An
interim analysis of overall survival showed no significant improve-
ment with crizotinib as compared with chemotherapy. This analy-
sis was nevertheless immature with a total of 96 deaths (40% of the
required events) and censoring of over 70% of patients in either
treatment arm. In addition, the analysis was likely confounded by
the high crossover rate of patients in the chemotherapy group,
with nearly 90% of patients on the chemotherapy arm crossing
over to the other arm upon disease progression. The response
rates were 65% with crizotinib, as compared with 20% with
chemotherapy. Common adverse events associated with crizotinib
were visual disorder, gastrointestinal side effects, and elevated liver
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FIGURE 1 |The ALK signaling pathway with its cross-talk with other pathways involved in the resistance to ALK-inhibitors. Adapted from
Tabbo et al. (47).
aminotransferase levels. Given the positive response rates with
crizotinib, multiple phase III trials are currently in progress to
address the efficacy of crizotinib as first-line therapy. Details of
these trials, including patient population and their respective pri-
mary endpoints, are summarized in Table S1 in Supplementary
Material.
One challenging clinical problem remains the treatment of
ALK+NSCLC patients with brain metastasis. These patients suffer
from an adverse impact on quality of life and survival. Although
it has been shown that crizotinib is effective for brain metas-
tasis, it is penetration into cerebrospinal fluid (CSF) has been
demonstrated to be very poor (8). Costa et al. measured the CSF-
to-plasma ratio of crizotinib being only at 0.0026 (9). Past expe-
rience with erlotinib and gefitinib in patients with EGFR-mutated
lung cancer has uncovered similar challenges: despite good sys-
temic control of disease, a subset of patients would progress in
the CNS, without any new acquired resistance mechanism, owing
to the poor penetration of these TKIs in the CSF. Although
pulse EGFR–TKIs doses have been used in this setting, there is
limited data to support its use with crizotinib (10). Newer gener-
ation of ALK-inhibitors with better CSF penetration are currently
under study.
RESISTANCE MECHANISMS OF CRIZOTINIB
In order to understand the rationale behind the majority of ongo-
ing clinical trials involving ALK+NSCLC patients, it is important
to survey the currently known mechanism of resistance to crizo-
tinib. ALK-dependant resistance mechanism occurs upon muta-
tions in the tyrosine kinase (TK) domain, and activation of alter-
native signaling pathways. Alternatively, true ALK-independent
resistance may arise through the outgrowth of clones that do
not harbor an ALK gene fusion and contain a separate activated
oncogene (11). Given that multiple resistance mechanisms are
occasionally found within the same biopsy specimen, as well as
different resistance mechanisms may be found in separate tumor
deposits within the same patient, it is important to consider re-
biopsy of the tumor upon progression on treatment, whenever
technically feasible, to correctly identify the resistance mechanism
accounting for progression of disease (12).
MUTATIONS IN TARGET TYROSINE KINASES
Past experience with the use of TKIs in chronic myelogenous
leukemia as well as EGFR-mutated lung cancer teaches us that most
common mechanisms of resistance to this class of medications are
secondary mutations in the TK domains (13). This also holds true
for crizotinib, given that mutations in the TK domains of the dif-
ferent targets of crizotinib is currently the best studied and most
prevalent form of resistance to this drug, accounting for up to 25%
of all cases resistant to ALK therapy (14).
The first major “gatekeeper” mutation identified in the TK
domain of EML4–ALK involves the substitution of leucine for
a methionine at position 1196 (L1196M) of the kinase domain of
ALK, thus creating a mutant bulky amino-acid side chain in the
ATP-binding pocket of the receptor, ultimately interfering with
the binding of crizotinib to its receptor (15). This is analogous
to the EGFR T790M mutation in the ATP biding pocket of the
EGFR, which is the most common mechanism of resistance in
EGFR-mutated lung cancer (12).
Tissue analysis of harvested tumor cells from patients resis-
tant to crizotinib has demonstrated other non-gatekeeper sec-
ondary mutations in the ALK TK receptor. ALK secondary muta-
tions in NSCLC are distributed throughout the kinase domain,
including the solvent front (G1202R, S1206Y), ATP-binding
pocket (G1269A), and N-terminal to the C-helix (1151Tins,
F1174L, L1152R, and C1156Y) (11, 15–20). The prevalence and
clinical significance of these secondary mutations remains to
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be elucidated. Of interest, a separate secondary ALK mutation,
F1174L, has also been identified in inflammatory myofibroblastic
tumors (21).
Crizotinib is an inhibitor of multiple TKIs beside ALK, includ-
ing ROS1 oncogene. A recent report of a G2032R mutation in the
ROS1 TK domain leading to crizotinib resistance has also been
identified (22). Although this mutation does not lie at the gate-
keeper position, it confers resistance to ROS1 kinase inhibition
through steric interference with drug binding.
ACTIVATION OF ALTERNATIVE PATHWAYS
Activation of alternative downstream signaling pathways, even in
the setting of complete ALK receptor inhibition, is increasingly rec-
ognized as mechanisms of resistance to crizotinib. These include
activation of the EGFR, heat shock protein 90 (HSP90), and the
PI3K/AKT/mTOR pathways. The activation of these alternative
pathways is present in up to 20% of patients (23).
Recent data from cell line experiments showed the activation
of EGFR to be associated with ALK resistance (18). This was fur-
ther corroborated with clinical analysis of tumor cells biopsied
from patients resistant to ALK therapy (24). In most studies, the
activation of EGFR occurred through increased phosphorylation
and upregulation of EGFR ligands, such as amphiregulin, rather
than being caused by mutations in the EGFR gene itself (18, 25).
Although ALK mutations are usually mutually exclusive to other
driver mutations such as EGFR, there have been reports of de novo
mutation of the EGFR gene in patients and cell lines treated with
crizotinib, accounting for resistance to this drug (11, 24, 26, 27).
The PI3K/AKT/mTOR pathway is an intracellular signaling
pathway important in cell cycle regulation and apoptosis also
implicated in resistance to ALK-targeted therapy. Recent ALK-
resistant cell line analysis revealed that the activation of the mTOR
pathways was associated with increased autophagy of the ALK
receptor thus leading to decreased response to crizotinib treatment
(28). The exact mechanism by which the ALK receptor induces
activation of the mTOR pathway remains to be elucidated, but
inhibition of AKT by phosphorylation seems to play a key factor.
One study showed synergistic in vitro growth inhibitory activity
of ALK inhibitor when combined with an mTOR inhibitor (29).
The clinical significance of mTOR activation in NSCLC patients
remains to be elucidated.
HSP90 is a highly abundant and ubiquitous molecular chap-
erone, which plays an essential role in many cellular processes
including cell cycle control, hormone signaling, as well as pro-
tein folding, and degradation. The ALK receptor is one of the
many client proteins of HSP90. HSP90 inhibition induced loss
of EML4-ALK expression and depletion of multiple oncogenic
signaling proteins in ALK-driven NSCLC cell lines (30). These
results were further corroborated in murine models of NSCLC as
well as anecdotal case reports of tissues derived from ALK therapy
resistant patients (31, 32).
ONGOING CLINICAL TRIALS INVOLVING NEW-GENERATION
ALK-INHIBITORS AND COMBINATION THERAPY
Most ongoing trials in ALK+ NSCLC patients involve newer
generation ALK-inhibitors or combination therapy targeting cur-
rently known resistance mechanism to crizotinib. These include
agents with activity against NSCLC with the L1196M gate-
keeper mutation or the ROS1 mutation, as well as combina-
tion therapy targeting the EGFR and HSP90 proteins/pathways.
A summary of these trials are presented in Table 1. Current
evidence for some of these new-generation ALK-inhibitors are
presented here.
CERITINIB (LDK378)
Ceritinib (LDK378, Novartis) is a novel and potent selective TKI
targeting ALK. Results from a recent phase I/II study of this
drug in both crizotinib-naïve and crizotinib-resistant patients
have been published (33). The maximum tolerated dose of cer-
itinib was 750 mg once daily. Dose-limiting toxic events included
diarrhea, vomiting, dehydration, elevated aminotransferase levels,
and hypophosphatemia. Among 114 patients with NSCLC who
received at least 400 mg of Ceritinib per day, the overall response
rate was 58%. For 80 patients previously treated with crizotinib, the
response rate was 56%. Responses were observed in patients with
various resistance mutations in ALK, including L1196M, and in
patients without detectable mutations. The median progression-
free survival of patients receiving at least 400 mg of ceritinib
was 7 months. Based on these findings, Ceritinib has recently
been granted FDA approval for treatment of patients with ALK+
NSCLC in the second-line setting following failure or intolerance
to crizotinib.
Multiple trials are nevertheless ongoing for this drug.
These include three phase II trials of ceritinib for crizotinib-
resistant patients (NCT01685060; NCT02040870) and crizotinib-
naïve patients (NCT01685138). One phase II study is looking
specifically at patients with ROS1 mutation (NCT01964157).
Two phase III trials are comparing ceritinib with standard
chemotherapy in patients previously treated with platinum-based
chemotherapy (NCT01828112), and chemotherapy-naïve patients
(NCT01828099). One phase I study is assessing the combination
of ceritinib with a HSP90 inhibitor (NCT01772797).
ALECTINIB (CH5424802/RO5424802)
Alectinib (Chugai and Roche Pharmaceuticals) is a highly potent
selective ALK inhibitor with activity against L1196M gatekeeper
mutation as well as other secondary mutations such as F1174L
and R1275Q (34, 35). Results from a recent phase I/II study with
alectinib in a Japanese population have been published (36). In
the phase I study, alectinib was given up to a maximum dose of
300 mg twice daily without dose-limiting toxicity. In the phase
II part of the study, 40/46 (87%) of patients achieved a par-
tial response within 6 weeks of treatment. Two patients had a
complete response. Median PFS had not been reached at the
time of the report. Responses were seen in brain metastases in
three patients. Grade 3 adverse events including neutropenia and
increase creatine phosphokinase occurred in 12 (26%) of patients.
Three phase II/III trials with alectinib are in progress in
crizotinib-naïve (ALEXA trial-NCT02075840) as well as in
crizotinib-resistant (NCT01871805; NCT01801111) patients.
AP26113
AP26113 (Ariad Pharmaceuticals) is a novel inhibitor of ALK
with activity against L1196M gatekeeper mutation as well as
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Table 1 | Ongoing clinical trials involving novel ALK- and HSP90-inhibitors in NSCLC.
ONGOING CLINICALTRIALS INVOLVING NOVELALK-INHIBITORS
Drug Company Activity against Activity against Ongoing trials Study phase Previous treatment
other kinases L1196M mutation
LDK378 (ceritinib) Novartis IFG-1R Yes NCT01772797 Phase I None
c-MET NCT02040870 Phase I/II Crizotinib/chemotherapy
NCT01685138 Phase II 0-3 lines of chemotherapy
NCT01685060 Phase II Crizotinib or 1-3 lines of chemotherapy
NCT01947608 Phase II Crizotinib
NCT01964157 Phase II 1 line of chemotherapy
NCT01828099 Phase III None
NCT01828112 Phase III Crizotinib
CH5424802/
RO5424802
(alectinib)
Roche/Chugai ROS1 Yes NCT01588028 Phase I
NCT01871805 Phase II Crizotinib
NCT01801111 Phase II Crizotinib
NCT02075840 Phase III
AP26113 Ariad EGFR Unknown NCT01449461 Phase I/II Refractory to standard therapy
ROS1 NCT02094573 Phase II Crizotinib
ASP3026 Astellas ROS1 Yes NCT01401504 Phase I Refractory to standard therapy
NCT01284192 Phase I Refractory to standard therapy
TSR-001 Tesaro Unknown Yes NCT02048488 Phase I None
PF-06463922 Pfizer EGFR Unknown NCT01970865 Phase I/II None
ROS1
X-396 Xcovery Unknown Yes NCT01625234 Phase I None
ONGOING CLINICALTRIALS INVOLVING HSP90 INHIBITORS
Drug Company Ongoing trials Study phase Combination therapy Previous treatment
AUY922 Novartis NCT01772797 Phase I LDK378 None
NCT01752400 Phase II Crizotinib
NCT01124864 Phase II Two lines of chemotherapy
NCT01922583 Phase II One line of chemotherapy
STA-9090 Synta NCT01579994 Phase I/II Crizotinib Standard chemotherapy
NCT01562015 Phase II Three lines of therapy
IPI-504 Infinity NCT01228435 Phase II Refractory to standard therapy
AT13387 Astex NCT01712217 Phase I/II Crizotinib Crizotinib
DS-2248 Daiichi Sankyo NCT01288430 Phase I Crizotinib
against ROS1 and EGFR (including mutant form with the
T790M gatekeeper mutation) (37). In an ongoing phase I/II
study (NCT01449461), the established dose was at 180 mg once
daily with good antitumor activity in ALK+ NSLC patients (38).
Objective response was observed in 15/24 (63%) patients (1
complete response and 14 partial responses), including 12/16
(75%) in patients resistant to crizotinib. Of interest, 4/5 patients
with brain metastasis had objective responses as well. The most
common treatment-related adverse events were nausea (33%),
fatigue (22%), and diarrhea (20%). A confirmatory phase II
studies in crizotinib-resistant (NCT02094573) is currently in
progress.
OTHER NEW-GENERATION ALK AGENTS
Multiple other new-generation ALK agents are currently under
phase I study. These include TSR-001, ASP3026, PF-06463922, as
well as X-396 (39–42). Details about these studies can be found in
Table 1.
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HSP90 INHIBITORS
Pre-clinical studies involving HSP90 inhibitors in ALK+ NSCLC
led to decreased ALK fusion protein levels in vitro, and led to tumor
regression in in vivo models (43). Currently, multiple HSP90
inhibitors are in phase I/II clinical trials involving ALK+ NSCLC
patients, either as stand-alone drugs or in combination with other
ALK-inhibitors such as crizotinib. Details about ongoing studies
can be found in Table 1.
Early results from phase II studies involving IPI-504 (Infinity
Pharma) in three NSCLC patients resulted in two partial responses
and one case of prolonged stable disease (44). In another phase II
study of ganetespib (STA-9090), 4/8 patients had partial responses
and three patients had stable disease (45). The most common
adverse effects were diarrhea, fatigue, nausea, and anorexia. Two
patients in this study died of cardiac arrest and renal failure asso-
ciated with ganetespib. There has also been one case report of a
crizotinib-resistant ALK+ NSCLC with an objective response to
this drug (31). AUY922 (Novartis) has been studied as a single
agent in both crizotinib-resistant and – naïve patients. Objective
response was achieved in 6/21 (29%) of patients, 4 of which were
crizotinib-naïve and remainder 2 had been previously treated with
crizotinib (46).
SUMMARY AND CONCLUSION
The identification of the ALK fusion protein in 2007 and the
fast development and approval of a FDA targeted treatment in
<5 years constitutes a remarkable feat in the field of targeted ther-
apies. Crizotinib holds many promises from its early debut in
treatment-refractory NSCLC patients. Final results from phase
III randomized trials using Crizotinib as a first-line therapy
are eagerly awaited for. Despite excellent response in the initial
stages, most patients develop resistance to crizotinib. Elucidating
resistance mechanism and subsequently developing therapeutic
strategies to overcome resistance to ALK-inhibitors constitutes
a priority, with the vast majority of ongoing clinical trials in
this field involving new-generation ALK-inhibitors or combina-
tion therapy with other targeted agents. Key questions remain
on how to correctly identify the resistance mechanism of a
tumor progressing on ALK-targeted therapy given re-biopsy is
often technically challenging and resource intensive, as well as on
how to correctly identify and stream the correct combination of
therapies to the appropriate patient populations as first-line ther-
apy. The ongoing Q-CROC-05 multicenter phase IV clinical trial
(NCT02041468) will aim to shed some light on these important
clinical issues.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at http://www.frontiersin.org/Journal/10.3389/fonc.2014.
00174/abstract
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